ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2440

Ambispective, Multicenter Registry of Treatment with Anifrolumab in Real Life in Patients with Systemic Lupus Erythematosus from Spanish Rheumatology Departments (ANIFRO-Reu): Efficacy, Safety and Patient’s Characteristics
Abstract Number: 0577

AMH Titers in Women with Axial Spondyloarthritis Are Significantly Lower Compared to the General Population: An Analysis of the 10-year Follow-up of the DESIR Cohort
Abstract Number: 0942

An Aged K/BxA Arthritis Mouse Model Develops Features of Interstitial Lung Disease with Pulmonary Fibrosis and Bronchus-Associated T-Cell Aggregates Without a Pulmonary Insult, and Correlates with Worsening Arthritis Scores
Abstract Number: 0493

An Algorithm Pipeline for Automated Metrical Analysis of Joint Swelling in Rheumatoid Arthritis via Smartphone Hand Photographs
Abstract Number: 1286

An Analysis of Diversity, Equity, and Inclusion Initiatives in US ACGME-accredited Adult Rheumatology Fellowship Programs
Abstract Number: 1029

An Analysis of Osteoporosis Screening in Males vs. Females Across Lehigh Valley Health Network
Abstract Number: 0229

An Early Inflammatory Cardiac Phenotype and Association with Future Coronary Plaque Burden in Rheumatoid Arthritis
Abstract Number: 1211

An Evaluation of the Efficacy, Pharmacokinetics and Safety, of the Transient Receptor Potential Vanilloid 1 (TRPV1) Agonist RTX-GRT7039 – a Placebo-controlled Study in Patients with Osteoarthritis Knee Pain
Abstract Number: 0781

An Expanded Cytotoxic CD8 T Cell Population Regulated by CD155-CD226 in SSc-ILD
Abstract Number: 0532

An Immune-molecular Signature Specifically Modulated by JAK Inhibitors Ex Vivo May Serve as a Predictor of Therapy Response In Vivo to These Drugs
Abstract Number: 0343

An Interlaboratory Variability Study of Detection Methods for Myositis-Specific and Myositis-Associated Autoantibodies in Sera from Patients with Idiopathic Inflammatory Myopathies
Abstract Number: 2111

An International Patient Survey to Identify Candidate Items for Classifying Early-Stage Symptomatic Knee Osteoarthritis
Abstract Number: 1273

An Investigation of Traumatic Events and Mental Health in cSLE
Abstract Number: 2158

An MVPA Is MVPA Is MVPA, or Is It? Impact of the Definition of Moderate to Vigorous Physical Activity (MVPA) on Its Amount in Persons with Advanced Knee Osteoarthritis
Abstract Number: 1423

An Observational Analytical Study on HCV Patients with Sicca Manifestations Before and After Direct-Acting Antivirals in Comparison with Sjogren’s Disease; Infection versus Autoimmunity

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].